Since patients with multiple myeloma (MM) have shown high DKK1 levels that were correlated with osteolytic bone damage, an anti-DKK1 neutralizing agent has been developed and clinically used in MM [45,46]. This evidence concerns the gene DKK1 and plasma cell myeloma.